About Us ParAllele - About Us
The ParAllele Advantage
People
History
Events
Alliances

ParAllele Press Release

Contacts

J. Clark Mason, PhD
Senior Director Product Marketing
Tel: ext. 7584

For ParAllele BioScience Inc.
Jennifer Larson
Tel:

ParAllele Announces Largest Ever Assay Panel Of Non-Synonymous SNPs -Promises a High Pay Off When Used In Disease Association Studies

South San Francisco, CA, April 19th, 2005 - ParAllele BioScience, Inc., announced today that it has doubled the number of available non-synonymous SNPs from the original 10,000 to a total of 20,000 SNPs that can be used in human genotyping studies. This increased assay panel, which in its earlier version was already the largest panel on the market, is immediately available through the ParAllele Genotyping Service. The enlarged non-synonymous coding SNP panel represents more than 10,000 human genes with SNPs that code for amino acid changes the changes that are believed to have the greatest impact on phenotype.

The assay panel is the latest offering from ParAllele. It was developed using the company's enabling technology of Molecular Inversion Probes that results in extremely high levels of multiplexing, essential for current genotyping demands. Unlike the company's earlier panel, which was comprised solely of validated SNPs from the public domain, this latest panel also included some of those selected by ParAllele from >25,000 previously unvalidated SNPs. The final SNP selection for the enlarged panel was achieved by genotyping approximately 300 individuals from three ethnic populations accounting for >8 million genotypes. The entire assay design, manufacture of the panel, genotyping and validation was completed at ParAllele BioScience, Inc. in less than 3 months.

"This enlarged panel to 20,000 fully validated non-synonymous SNPs, not only represents a cost effective way of achieving whole genome analysis, but has the potential of an extremely high pay off, since the SNPs that we have selected for this assay panel represent those most likely to be associated with a functional consequence" said Malek Faham, MD, Ph.D, Co-founder and Director of Research at ParAllele.

About ParAllele Bioscience

ParAllele BioScience, Inc. is accelerating healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The understanding of how subtle genetic variations contribute to disease risk, prognosis and drug response will lead to new and more effective drugs, predictive diagnosis, and the ability to better tailor therapies to individual patients. Headquartered in South San Francisco, California, ParAllele BioScience was founded by a team of leading researchers from the Stanford Genome Technology Center and Uppsala University. The company's investors include Abingworth Management, Index Ventures, Mohr Davidow Ventures, and Versant Ventures. For more information about ParAllele, please visit the company's website at: parallelebio.com.

ParAllele, MegAllele are trademarks of ParAllele BioScience, Inc.. All other trademarks and registered trademarks are the property of their respective owners.

top^